STAT+: AstraZeneca’s experimental COPD treatment posts strong results in late-stage studies

[AstraZeneca’s Novel Pulmonary Therapy Shows Significant Reduction in COPD Exacerbations in Late-Stage Clinical Trials]

AstraZeneca’s novel pulmonary therapy demonstrated a substantial decline in acute COPD exacerbations during phase 3 clinical testing, revealing strong potential for patients facing potentially life‑threatening events of lung dysfunction. Phase 3 trial findings indicated approximately a 30% reduction in COPD exacerbation rates among participants over a one‑year period, marking a promising development for the debilitating condition.

The Phase 3 studies of the injected formulation, nicknamed “tozo” by clinicians, delivered encouraging results that reflect continued strength behind AstraZeneca despite recent setbacks with certain major therapeutic programs. Projected revenue could exceed billions annually across both COPD and complementary indications such as asthma, where the drug’s efficacy profile offers additional market opportunity.

“The data presented at the European Respiratory Society’s annual conference in Barcelona and published in the New England Journal of Medicine shows that tozokimab significantly reduces exacerbations—any sudden worsening requiring medical care, such as severe coughing or breathlessness—by roughly 30% across the full participant cohort over a year.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Already have an account? Log in

To read the rest of this story subscribe to STAT+. Subscribe

Source link